[{"id":"04dc5f85-501f-4bef-9699-930885ac6468","acronym":"PACIFIC-8","url":"https://clinicaltrials.gov/study/NCT05211895","created_at":"2022-01-29T18:05:07.133Z","updated_at":"2025-02-25T14:02:42.829Z","phase":"Phase 3","brief_title":"A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC","source_id_and_acronym":"NCT05211895 - PACIFIC-8","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • PD-L1","pipe":" | ","alterations":" EGFR wild-type • ALK wild-type","tags":["EGFR • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR wild-type • ALK wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • domvanalimab (AB154)"],"overall_status":"Recruiting","enrollment":" Enrollment 860","initiation":"Initiation: 02/18/2022","start_date":" 02/18/2022","primary_txt":" Primary completion: 06/27/2028","primary_completion_date":" 06/27/2028","study_txt":" Completion: 08/30/2030","study_completion_date":" 08/30/2030","last_update_posted":"2025-02-19"},{"id":"c0529000-1eea-42c3-9cae-d983a7189b6c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05943795","created_at":"2023-07-13T18:10:45.267Z","updated_at":"2025-02-25T15:36:23.229Z","phase":"Phase 3","brief_title":"A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma","source_id_and_acronym":"NCT05943795","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • ROS1 • NTRK","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • BRAF mutation • HER-2 amplification • BRAF V600 • KRAS G12D • EGFR wild-type • RET mutation • ALK wild-type • ROS1 fusion • ROS1 rearrangement • RET rearrangement • KRAS G12 • KRAS amplification • NTRK fusion","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • BRAF mutation • HER-2 amplification • BRAF V600 • KRAS G12D • EGFR wild-type • RET mutation • ALK wild-type • ROS1 fusion • ROS1 rearrangement • RET rearrangement • KRAS G12 • KRAS amplification • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • izalontamab (SI-B001)"],"overall_status":"Recruiting","enrollment":" Enrollment 584","initiation":"Initiation: 07/14/2023","start_date":" 07/14/2023","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2025-02-11"},{"id":"3ec23c8c-cbf9-4200-8659-8f1562c5185d","acronym":"PACIFIC-9","url":"https://clinicaltrials.gov/study/NCT05221840","created_at":"2022-02-05T18:29:09.587Z","updated_at":"2025-02-25T16:38:50.332Z","phase":"Phase 3","brief_title":"A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05221840 - PACIFIC-9","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • PD-L1","pipe":" | ","alterations":" EGFR wild-type • ALK wild-type","tags":["EGFR • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR wild-type • ALK wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • oleclumab (MEDI9447) • monalizumab (IPH2201)"],"overall_status":"Recruiting","enrollment":" Enrollment 999","initiation":"Initiation: 02/07/2022","start_date":" 02/07/2022","primary_txt":" Primary completion: 05/29/2026","primary_completion_date":" 05/29/2026","study_txt":" Completion: 05/31/2030","study_completion_date":" 05/31/2030","last_update_posted":"2025-02-07"},{"id":"4f876388-d941-4723-8bd3-32c5bf27eff5","acronym":"MDT-BRIDGE","url":"https://clinicaltrials.gov/study/NCT05925530","created_at":"2023-06-29T14:09:16.530Z","updated_at":"2025-02-25T16:33:33.747Z","phase":"Phase 2","brief_title":"Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)","source_id_and_acronym":"NCT05925530 - MDT-BRIDGE","lead_sponsor":"AstraZeneca","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR wild-type • ALK wild-type","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR wild-type • ALK wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 02/22/2024","start_date":" 02/22/2024","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 08/27/2027","study_completion_date":" 08/27/2027","last_update_posted":"2025-02-07"},{"id":"b5311e32-e5a1-4a67-a74a-af139d0dfb7e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04958811","created_at":"2021-07-12T15:53:06.793Z","updated_at":"2025-02-25T16:38:29.835Z","phase":"Phase 2","brief_title":"Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC","source_id_and_acronym":"NCT04958811","lead_sponsor":"Georgetown University","biomarkers":" ALK • ROS1","pipe":" | ","alterations":" PD-L1 expression • ALK wild-type • ROS1 wild-type","tags":["ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • ALK wild-type • ROS1 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • tiragolumab (RG6058)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 12/21/2021","start_date":" 12/21/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-06"},{"id":"6d02b2cb-e725-4564-937c-5c8ad5cce7e3","acronym":"SILK BM","url":"https://clinicaltrials.gov/study/NCT03955198","created_at":"2021-01-18T19:27:56.449Z","updated_at":"2025-02-25T16:31:50.998Z","phase":"Phase 2","brief_title":"A Trial Evaluating Stereotactic Radiotherapy Plus Durvalumab Continuation for Patients With NSCLC Metachronous Oligometastatic Disease Under Durvalumab Consolidation Following Chemoradiation","source_id_and_acronym":"NCT03955198 - SILK BM","lead_sponsor":"Institut Claudius Regaud","biomarkers":" EGFR • ALK • CTLA4","pipe":" | ","alterations":" EGFR wild-type • ALK wild-type","tags":["EGFR • ALK • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR wild-type • ALK wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab)"],"overall_status":"Completed","enrollment":" Enrollment 4","initiation":"Initiation: 05/27/2021","start_date":" 05/27/2021","primary_txt":" Primary completion: 08/26/2024","primary_completion_date":" 08/26/2024","study_txt":" Completion: 08/26/2024","study_completion_date":" 08/26/2024","last_update_posted":"2024-09-19"},{"id":"122e5ddf-e06a-4539-a4fb-c6730d4e0338","acronym":"LATIFY","url":"https://clinicaltrials.gov/study/NCT05450692","created_at":"2022-07-11T12:56:21.525Z","updated_at":"2024-07-02T16:35:00.482Z","phase":"Phase 3","brief_title":"A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy","source_id_and_acronym":"NCT05450692 - LATIFY","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR wild-type • ALK wild-type","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR wild-type • ALK wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • docetaxel • ceralasertib (AZD6738)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 563","initiation":"Initiation: 09/15/2022","start_date":" 09/15/2022","primary_txt":" Primary completion: 05/12/2025","primary_completion_date":" 05/12/2025","study_txt":" Completion: 08/22/2025","study_completion_date":" 08/22/2025","last_update_posted":"2024-05-29"},{"id":"124724a9-c433-4ebd-b30a-756fba93c068","acronym":"LOTOS","url":"https://clinicaltrials.gov/study/NCT05941897","created_at":"2023-07-12T16:10:18.523Z","updated_at":"2024-07-02T16:35:02.636Z","phase":"Phase 2","brief_title":"A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy","source_id_and_acronym":"NCT05941897 - LOTOS","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR wild-type • ALK wild-type","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR wild-type • ALK wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • ceralasertib (AZD6738)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 06/21/2023","start_date":" 06/21/2023","primary_txt":" Primary completion: 07/29/2024","primary_completion_date":" 07/29/2024","study_txt":" Completion: 07/29/2025","study_completion_date":" 07/29/2025","last_update_posted":"2024-05-20"},{"id":"820e22ed-50fe-40f0-aa7c-051ded02330b","acronym":"CA209-117","url":"https://clinicaltrials.gov/study/NCT01928576","created_at":"2021-01-18T08:42:53.521Z","updated_at":"2025-02-25T14:34:17.894Z","phase":"Phase 2","brief_title":"Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.","source_id_and_acronym":"NCT01928576 - CA209-117","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" EGFR • KRAS • ALK","pipe":" | ","alterations":" EGFR mutation • EGFR exon 19 deletion • ALK positive • ALK rearrangement • EGFR wild-type • ALK wild-type • ALK translocation","tags":["EGFR • KRAS • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 19 deletion • ALK positive • ALK rearrangement • EGFR wild-type • ALK wild-type • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • azacitidine • Jingzhuda (entinostat) • Onureg (azacitidine oral)"],"overall_status":"Completed","enrollment":" Enrollment 143","initiation":"Initiation: 11/06/2013","start_date":" 11/06/2013","primary_txt":" Primary completion: 04/04/2023","primary_completion_date":" 04/04/2023","study_txt":" Completion: 04/04/2023","study_completion_date":" 04/04/2023","last_update_posted":"2024-05-03"},{"id":"f2b35136-f790-410c-b54a-4f61af16101b","acronym":"ZWI-ZW25-101","url":"https://clinicaltrials.gov/study/NCT02892123","created_at":"2021-01-17T17:13:28.525Z","updated_at":"2024-07-02T16:35:08.789Z","phase":"Phase 1","brief_title":"Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers","source_id_and_acronym":"NCT02892123 - ZWI-ZW25-101","lead_sponsor":"Jazz Pharmaceuticals","biomarkers":" EGFR • HER-2 • KRAS • ALK • ROS1","pipe":" | ","alterations":" HER-2 positive • HER-2 overexpression • EGFR wild-type • KRAS wild-type • ALK wild-type • RAS wild-type • EGFR wild-type + ALK wild-type • ALK-ROS1 fusion","tags":["EGFR • HER-2 • KRAS • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 overexpression • EGFR wild-type • KRAS wild-type • ALK wild-type • RAS wild-type • EGFR wild-type + ALK wild-type • ALK-ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • capecitabine • Tukysa (tucatinib) • vinorelbine tartrate • Ziihera (zanidatamab-hrii)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 279","initiation":"Initiation: 09/30/2016","start_date":" 09/30/2016","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-04-18"},{"id":"f13bc4e9-84c6-44f1-8827-fcfe07499b5c","acronym":"PRIME_LUNG","url":"https://clinicaltrials.gov/study/NCT05222087","created_at":"2022-02-05T18:29:12.695Z","updated_at":"2024-07-02T16:35:14.201Z","phase":"Phase 1","brief_title":"PRIME_LUNG: Primary Radiotherapy In MEtastatic Lung Cancer - A Pilot Study","source_id_and_acronym":"NCT05222087 - PRIME_LUNG","lead_sponsor":"Peter MacCallum Cancer Centre, Australia","biomarkers":" EGFR • ROS1","pipe":" | ","alterations":" ALK wild-type • ROS1 wild-type","tags":["EGFR • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK wild-type • ROS1 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • paclitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 01/03/2022","start_date":" 01/03/2022","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 04/01/2024","study_completion_date":" 04/01/2024","last_update_posted":"2024-03-18"},{"id":"258dd981-3155-4a65-b439-66d48123d14a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05020457","created_at":"2021-08-25T14:53:14.347Z","updated_at":"2024-07-02T16:35:21.410Z","phase":"Phase 2","brief_title":"SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.","source_id_and_acronym":"NCT05020457","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR wild-type • ALK wild-type • EGFR wild-type + ALK wild-type","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR wild-type • ALK wild-type • EGFR wild-type + ALK wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tagrisso (osimertinib) • paclitaxel • docetaxel • pemetrexed • izalontamab (SI-B001)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 12/07/2021","start_date":" 12/07/2021","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 04/01/2024","study_completion_date":" 04/01/2024","last_update_posted":"2024-01-31"},{"id":"c202d09f-4287-4463-8629-079b1034deac","acronym":"","url":"https://clinicaltrials.gov/study/NCT03156114","created_at":"2021-01-18T15:33:42.030Z","updated_at":"2024-07-02T16:35:44.324Z","phase":"Phase 1","brief_title":"This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.","source_id_and_acronym":"NCT03156114","lead_sponsor":"Boehringer Ingelheim","biomarkers":" EGFR • ALK • TMB • MSI","pipe":" | ","alterations":" PD-L1 expression • TMB-H • MSI-H/dMMR • PD-L1 overexpression • EGFR wild-type • ALK wild-type","tags":["EGFR • ALK • TMB • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • TMB-H • MSI-H/dMMR • PD-L1 overexpression • EGFR wild-type • ALK wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ezabenlimab (BI 754091) • miptenalimab (BI 754111)"],"overall_status":"Completed","enrollment":" Enrollment 172","initiation":"Initiation: 06/13/2017","start_date":" 06/13/2017","primary_txt":" Primary completion: 03/09/2023","primary_completion_date":" 03/09/2023","study_txt":" Completion: 06/06/2023","study_completion_date":" 06/06/2023","last_update_posted":"2023-06-29"},{"id":"3a7c465c-37ae-4f58-8571-e00377298b31","acronym":"INTEGRATE","url":"https://clinicaltrials.gov/study/NCT04563338","created_at":"2021-01-18T21:48:13.562Z","updated_at":"2024-07-02T16:35:45.484Z","phase":"Phase 2","brief_title":"An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE)","source_id_and_acronym":"NCT04563338 - INTEGRATE","lead_sponsor":"University Health Network, Toronto","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" EGFR wild-type • ALK wild-type","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR wild-type • ALK wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 06/04/2021","start_date":" 06/04/2021","primary_txt":" Primary completion: 12/05/2024","primary_completion_date":" 12/05/2024","study_txt":" Completion: 12/05/2024","study_completion_date":" 12/05/2024","last_update_posted":"2023-06-16"},{"id":"04a9b159-8750-41fc-9f7f-22b4395ff6ac","acronym":"","url":"https://clinicaltrials.gov/study/NCT05460481","created_at":"2022-07-15T16:05:34.868Z","updated_at":"2024-07-02T16:36:07.086Z","phase":"Phase 2","brief_title":"Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 Inhibitors","source_id_and_acronym":"NCT05460481","lead_sponsor":"Hunan Cancer Hospital","biomarkers":" EGFR • ROS1","pipe":" | ","alterations":" ALK wild-type • ROS1 wild-type","tags":["EGFR • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK wild-type • ROS1 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • Anniko (penpulimab-kcqx)"],"overall_status":"Recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 06/12/2022","start_date":" 06/12/2022","primary_txt":" Primary completion: 06/01/2023","primary_completion_date":" 06/01/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2022-07-20"},{"id":"0e99a14e-0588-4bdb-9b51-59ddd058b33a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04909034","created_at":"2021-06-01T17:53:35.346Z","updated_at":"2024-07-02T16:36:23.340Z","phase":"Phase 2","brief_title":"Safety and Potential Efficacy of MS-20 In Combination With Pembrolizumab for the Treatment of NSCLC","source_id_and_acronym":"NCT04909034","lead_sponsor":"Microbio Co Ltd","biomarkers":" EGFR • PD-L1 • ALK • ROS1","pipe":" | ","alterations":" ALK wild-type","tags":["EGFR • PD-L1 • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/20/2021","start_date":" 08/20/2021","primary_txt":" Primary completion: 06/30/2023","primary_completion_date":" 06/30/2023","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2021-10-07"},{"id":"1bacf18f-4d19-44c7-8a92-f00db536eed3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05055583","created_at":"2021-09-24T14:55:09.853Z","updated_at":"2025-02-25T16:26:42.014Z","phase":"Phase 2","brief_title":"Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSCLC","source_id_and_acronym":"NCT05055583","lead_sponsor":"Tang-Du Hospital","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • ALK mutation • ALK wild-type • ROS1 wild-type","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK mutation • ALK wild-type • ROS1 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/31/2021","start_date":" 08/31/2021","primary_txt":" Primary completion: 08/31/2023","primary_completion_date":" 08/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2021-09-24"},{"id":"22fc6479-c52f-4374-b978-970f04ec1f53","acronym":"CCICC-002b","url":"https://clinicaltrials.gov/study/NCT04836728","created_at":"2021-04-08T12:52:20.588Z","updated_at":"2024-07-02T16:36:32.210Z","phase":"Phase 2","brief_title":"Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to Treat Lung Cancer","source_id_and_acronym":"NCT04836728 - CCICC-002b","lead_sponsor":"Tianjin Medical University Cancer Institute and Hospital","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" ALK fusion • ALK wild-type","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK fusion • ALK wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • Tyvyt (sintilimab) • albumin-bound paclitaxel • pemetrexed"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 156","initiation":"Initiation: 04/01/2021","start_date":" 04/01/2021","primary_txt":" Primary completion: 06/01/2022","primary_completion_date":" 06/01/2022","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2021-04-08"},{"id":"32469782-836f-4468-a300-34932de87ee8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04193098","created_at":"2021-01-18T20:26:04.757Z","updated_at":"2024-07-02T16:36:43.606Z","phase":"Phase 1","brief_title":"Study of Autologous Cytotoxic T Lymphocyte Immunotherapy Combination With PD-1 Inhibitor in the Advanced NSCLC","source_id_and_acronym":"NCT04193098","lead_sponsor":"Tianjin Medical University Cancer Institute and Hospital","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" ALK fusion • ALK wild-type","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK fusion • ALK wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi)"],"overall_status":"Unknown status","enrollment":" Enrollment 10","initiation":"Initiation: 06/01/2019","start_date":" 06/01/2019","primary_txt":" Primary completion: 06/01/2021","primary_completion_date":" 06/01/2021","study_txt":" Completion: 06/01/2021","study_completion_date":" 06/01/2021","last_update_posted":"2020-07-07"},{"id":"b1a0acd9-acc6-4434-a8e1-a49ae9c69e8c","acronym":"CCICC-002","url":"https://clinicaltrials.gov/study/NCT03987867","created_at":"2021-01-18T19:36:33.029Z","updated_at":"2024-07-02T16:36:43.610Z","phase":"Phase 1","brief_title":"Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC","source_id_and_acronym":"NCT03987867 - CCICC-002","lead_sponsor":"Tianjin Medical University Cancer Institute and Hospital","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" ALK fusion • ALK wild-type","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK fusion • ALK wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • Tyvyt (sintilimab) • pemetrexed"],"overall_status":"Unknown status","enrollment":" Enrollment 30","initiation":"Initiation: 06/01/2019","start_date":" 06/01/2019","primary_txt":" Primary completion: 06/01/2021","primary_completion_date":" 06/01/2021","study_txt":" Completion: 06/01/2021","study_completion_date":" 06/01/2021","last_update_posted":"2020-07-07"},{"id":"8c304df1-30b9-42ae-94a2-7c26d92108b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT03656094","created_at":"2021-01-18T17:56:44.623Z","updated_at":"2024-07-02T16:36:52.774Z","phase":"Phase 2","brief_title":"Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 Inhibitors","source_id_and_acronym":"NCT03656094","lead_sponsor":"Samsung Medical Center","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR wild-type • ALK wild-type • EGFR wild-type + ALK wild-type","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR wild-type • ALK wild-type • EGFR wild-type + ALK wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • docetaxel • pemetrexed • vinorelbine tartrate"],"overall_status":"Unknown status","enrollment":" Enrollment 98","initiation":"Initiation: 11/01/2018","start_date":" 11/01/2018","primary_txt":" Primary completion: 11/01/2020","primary_completion_date":" 11/01/2020","study_txt":" Completion: 11/01/2021","study_completion_date":" 11/01/2021","last_update_posted":"2019-12-09"},{"id":"936af32e-f414-41ca-9777-943bff120db2","acronym":"","url":"https://clinicaltrials.gov/study/NCT03910127","created_at":"2021-01-18T19:14:45.678Z","updated_at":"2024-07-02T16:36:54.127Z","phase":"Phase 1","brief_title":"Study of TQB2450 Combined With Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（NSCLC）","source_id_and_acronym":"NCT03910127","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" PD-L1 expression • EGFR wild-type • ALK wild-type","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR wild-type • ALK wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • Andewei (benmelstobart)"],"overall_status":"Unknown status","enrollment":" Enrollment 90","initiation":"Initiation: 06/11/2019","start_date":" 06/11/2019","primary_txt":" Primary completion: 12/31/2020","primary_completion_date":" 12/31/2020","study_txt":" Completion: 06/30/2021","study_completion_date":" 06/30/2021","last_update_posted":"2019-10-30"},{"id":"89723393-dc0c-4d35-b358-5b8492b43d07","acronym":"SUNRISE","url":"https://clinicaltrials.gov/study/NCT04124731","created_at":"2021-01-18T20:09:10.654Z","updated_at":"2024-07-02T16:36:54.652Z","phase":"Phase 2","brief_title":"Combination Therapy of Sintilimab and Anlotinib as a First-line Treatment in Advanced NSCLC (SUNRISE)","source_id_and_acronym":"NCT04124731 - SUNRISE","lead_sponsor":"Shanghai Chest Hospital","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" PD-L1 expression • EGFR wild-type • ALK wild-type","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR wild-type • ALK wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Focus V (anlotinib) • Tyvyt (sintilimab)"],"overall_status":"Unknown status","enrollment":" Enrollment 98","initiation":"Initiation: 10/01/2019","start_date":" 10/01/2019","primary_txt":" Primary completion: 04/01/2021","primary_completion_date":" 04/01/2021","study_txt":" Completion: 04/01/2022","study_completion_date":" 04/01/2022","last_update_posted":"2019-10-11"},{"id":"ce3736cc-4e31-45d3-bb0f-4bd380fee0e4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03636685","created_at":"2021-01-18T17:51:27.412Z","updated_at":"2024-07-02T16:37:07.770Z","phase":"Phase 1/2","brief_title":"Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC","source_id_and_acronym":"NCT03636685","lead_sponsor":"Chinese Academy of Medical Sciences","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • ALK mutation • ALK wild-type • ROS1 mutation • ROS1 wild-type","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK mutation • ALK wild-type • ROS1 mutation • ROS1 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • Focus V (anlotinib) • pemetrexed"],"overall_status":"Unknown status","enrollment":" Enrollment 60","initiation":"Initiation: 08/15/2018","start_date":" 08/15/2018","primary_txt":" Primary completion: 08/14/2019","primary_completion_date":" 08/14/2019","study_txt":" Completion: 08/14/2020","study_completion_date":" 08/14/2020","last_update_posted":"2018-08-17"}]